Active	Status	Sponsor type	Region	Phase	Filter
4 Active 1 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Antonova, Elizaveta
NCT05216497: Efficacy and Safety of Ingavirin®, 90 mg Capsules in Patients With COVID-19	Completed	3	233	RoW	Ingavirin®, 90 mg capsules, Placebo	Valenta Pharm JSC	COVID-19	01/22	04/22
NCT04940182: A Study to Assess the Efficacy and Safety of XC221 in Patients With Mild COVID-19	Completed	3	274	RoW	XC221, Placebo	RSV Therapeutics LLC	Sars-CoV-2 Infection	08/22	11/22
NCT05544916: A Study to Evaluate the Safety and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory Infections	Completed	3	260	RoW	XC221, Placebo	Valenta Pharm JSC	Influenza, Respiratory Viral Infection	02/23	05/23
MMH-407-009, NCT06263881: Clinical Trial of the Efficacy and Safety of Raphamin in Combined Treatment of Community-acquired Pneumonia	Completed	3	370	RoW	Raphamin, MMH-407, Placebo	Materia Medica Holding	Community-acquired Pneumonia, Pneumonia	03/25	03/25

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Antonova, Elizaveta
NCT05216497: Efficacy and Safety of Ingavirin®, 90 mg Capsules in Patients With COVID-19	Completed	3	233	RoW	Ingavirin®, 90 mg capsules, Placebo	Valenta Pharm JSC	COVID-19	01/22	04/22
NCT04940182: A Study to Assess the Efficacy and Safety of XC221 in Patients With Mild COVID-19	Completed	3	274	RoW	XC221, Placebo	RSV Therapeutics LLC	Sars-CoV-2 Infection	08/22	11/22
NCT05544916: A Study to Evaluate the Safety and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory Infections	Completed	3	260	RoW	XC221, Placebo	Valenta Pharm JSC	Influenza, Respiratory Viral Infection	02/23	05/23
MMH-407-009, NCT06263881: Clinical Trial of the Efficacy and Safety of Raphamin in Combined Treatment of Community-acquired Pneumonia	Completed	3	370	RoW	Raphamin, MMH-407, Placebo	Materia Medica Holding	Community-acquired Pneumonia, Pneumonia	03/25	03/25